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Abstract: Some genetic polymorphisms of human ABC transporter genes are reportedly related to the risk of certain diseases and  
patients’ responses to medication. Human ABCC11 functions as an ATP-dependent efflux pump for amphipathic anions. One non-
synonymous SNP 538G>A (Gly180Arg) has been found to greatly affect the function and stability of de novo synthesized ABCC11 
(Arg180) variant protein. The SNP variant lacking N-linked glycosylation is recognized as a misfolded protein in the endoplasmic reticu-
lum (ER) and readily undergoes proteasomal degradation. This ER-associated degradation of ABCC11 protein underlies the molecular 
mechanism of affecting the function of apocrine glands. On the other hand, the wild type (Gly180) of ABCC11 is associated with wet-
type earwax, axillary osmidrosis, colostrum secretion from the mammary gland, and the potential susceptibility of breast cancer. Fur-
thermore, the wild type of ABCC11 reportedly has ability to efflux cyclic nucleotides and nucleoside-based anticancer drugs. The SNP 
(538G>A) of the ABCC11 gene is suggested to be a clinical biomarker for prediction of chemotherapeutic efficacy. Major obstacle to the 
successful chemotherapy of human cancer is development of resistance, and nucleoside-based chemotherapy is often characterized by in-
ter-individual variability. This review provides an overview about the discovery and the genetic polymorphisms in human ABCC11. Fur-
thermore, we focus on the impact of ABCC11 538G>A on the apocrine phenotype, patients’ response to nucleoside-based chemotherapy, 
and the potential risk of breast cancer. 
Keywords: Apocrine gland, tamoxifen, earwax, estrogen receptor, mastopathy, multidrug resistance, nucleoside, single nucleotide polymor-
phism (SNP). 
1. INTRODUCTION 
  Pharmacogenomics dealing with heredity and response to drugs 
is increasingly important, since it attempts to explain variability of 
one or another drug response and to search for the genetic basis of 
such variations or differences [1-5]. In fact, inter-individual vari-
ability in drug response and the emergence of adverse drug reac-
tions are critical issues in drug development as well as in clinical 
pharmacotherapy. Accumulating evidence strongly suggests that 
genetic polymorphisms in drug-metabolizing enzymes, transporters, 
receptors, and other drug targets are linked to inter-individual dif-
ferences in the efficacy and toxicity of many medications [6-9]. 
  During the past two decades, the role of carrier-mediated trans-
port in determining the pharmacokinetics of drugs has become in-
creasingly evident with the discovery of genetic variants that affect 
expression and/or function of a given drug transporter [6, 10]. Drug 
transporters, including ATP-binding cassette (ABC) transporters 
and solute carrier (SLC) transporters, are expressed at numerous 
epithelial barriers, such as intestinal epithelial cells, hepatocytes, 
renal tubular cells, the blood-brain barrier, and cancer cells [10]. 
  The ABC transporters are a family of large proteins in mem-
branes and are able to transport a variety of compounds including 
metabolites and drugs through membranes at the cost of ATP hy-
drolysis [11]. Physiological functions of ABC transporters include 
the transport of lipids, bile salts, toxic compounds, and peptides for 
antigen presentation or other purposes, such as ion channel-
regulation. The human genome contains 48 ABC transporter genes; 
at least 14 of these are reportedly associated with heritable human 
diseases [12]. The diseases that are included are rare and heavily 
transmitted in families. In fact, mutations in ABC transporter genes 
have been reported to be associated with inherited diseases includ-
ing
  Tangier disease T1 (ABCA1); Stargardt disease, retinitis pig-
mentosa and age-related macular degeneration (ABCA4); progres-
sive familial intrahepatic cholestasis (ABCB11); Dubin–Johnson 
syndrome (ABCC2); pseudoxanthoma elasticum (ABCC6); cystic 
fibrosis (CFTR/ABCC7); X-linked adrenoleukodystrophy (ABCD1 
and  ABCD2); some forms of Zellweger syndrome (ABCD3 and 
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 ABCD2), and sitosterolaemia (a rare lipid metabolic disorder inher-
ited as an autosomal recessive trait) (ABCG5 and ABCG8) [11]. 
Furthermore, it has recently been reported that SNPs in ABCC11 
and ABCG2 genes are related with axillary osmidrosis [13-15] and 
gout risk [16-18], respectively. Some additional ABC  transporter 
genes are also implicated in, or are candidates for, other metabolic 
inherited diseases (http://nutrigene.4t.com:80/humanabc.htm). In 
this context, mutations and genetic polymorphisms in ABC trans-
porter genes are considered important biomarkers for diagnosis of 
inherited diseases and prediction of the risk of drug-induced ad-
verse reactions or response to chemotherapy. Among such human 
ABC transporters, in this review article we will address human 
ABCC11 to discuss the potential impact of its genetic polymor-
phisms on the physiological function, breast cancer risk, and pa-
tients’ response to nucleoside-based chemotherapy. 
2. DISCOVERY OF HUMAN ABCC11 GENE 
  In 2001, three research groups, including us, independently 
cloned two novel ABC transporters named ABCC11 and ABCC12 
from the cDNA library of human adult liver [19-21]. These two 
genes have been found to be located on human chromosome 
16q12.1 in a tail-to-head orientation with a separation distance of 
about 20 kb (Fig. (1A)). The predicted amino acid sequences of 
both gene products show a high similarity to those of ABCC4 and 
ABCC5, suggesting that they have the typical structure of “full” 
ABC transporter (Fig. (1B)). However, there is no putative mouse 
or rat orthologous gene corresponding to human ABCC11 [22]. This 
fact indicates that ABCC11 is not an orthologous gene but rather a 
paralogous gene generated by gene duplication in the human ge-
nome. On the other hand, ABCC12 and its orthologous genes are 
found in different species including humans, primates, and rodents 
[22]. 
  Transcript analyses suggest that human ABCC11 mRNA is 
ubiquitously expressed in human adult and fetal tissues [19, 20]. In 
addition, we [19] and Bera et al. [21] demonstrated high levels of 
ABCC11 mRNA in breast cancer. The increased expression of 
ABCC11 wild type (WT) in breast cancer might be related with low 
levels of efficacy of chemotherapy, as discussed later in this review. 
  When transfected exogenously, the ABCC11 WT protein was 
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cells strain II (MDCK II) cells [23]. The substrate specificity of 
ABCC11 WT was characterized in more detail by an in vitro trans-
port assay with plasma membrane vesicles prepared from pig LLC-
PK1 cells transfected with an ABCC11 WT expression vector [24]. 
Their assay demonstrated that ABCC11 WT is able to transport a 
variety of lipophilic anions, including cyclic nucleotides, glu-
tathione conjugates such as leukotriene C4 (LTC4) and S-(2,4-
dinitrophenyl)-glutathione (DNP-SG), steroid sulfates such as es-
trone 3-sulfate (E13S) and dehydroepiandrostenedione 3-sulphate 
(DHEAS), glucuronides such as estradiol 17--D-glucuronide 
(E217G), monoanionic bile acids glycocholate and taurocholate, 
and folic acid and its analog methotrexate (MTX) (Fig. (2A)). Ki-
netic analyses suggest that cGMP and DHEAS are good substrates 
for ABCC11 (Table 1) [23, 24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). (A) The genomic structures of ABCC11 and ABCC12 genes on 
human chromosome 16q12.1. The cytogenetic location of the ABCC11 gene 
as well as the structures of exons and introns were analysed by BLAST 
searches on the human genome. The ABCC11 gene is encoded by a -68 kb 
gene consisting of 30 exons. A non-synonymous SNP: 538G>A 
(Gly180Arg), an earwax determinant, is in the exon 4 of ABCC11 gene. (B) 
Schematic illustration of ABCC11 structure and hitherto known non-
synonymous SNPs. ABCC11 has a total of 12 transmembrane (TM) regions 
and two intracellular ATP-binding cassettes. Asn838 and Asn844 residing in 
an extracellular loop between transmembrane helices TM7 and TM8 are N-
linked glycosylation sites in the ABCC11 WT protein. Locations of hitherto 
reported nonsynonymous SNPs and 27 (rare deletion mutation) are indi-
cated in the putative structure of ABCC11. G180R and 27 are related with 
the formation of dry-type earwax. 
 
3. REGULATION OF ABCC11 GENE EXPRESSION 
  In 2004 Bieche et al. [25] reported that ABCC11 was up-
regulated in estrogen receptor- -positive breast tumors, as com-
pared with normal breast tissue. Sarah Park et al. [26] investigated 
the mRNA levels of ABC transporter genes in breast cancer pa-
tients who underwent sequential weekly paclitaxel/FEC   
(5-fluorouracil, epirubicin and cyclophosphamide) neoadjuvant 
chemotherapy. Their analysis showed that the expression of 
ABCC11 was increased (fold ratio = 2.71) in the patients with the 
residual disease as compared with the patients with no pathologic 
evidence of any residual invasive cancer cells in breast. 
 More  recently,  Honorat  et al. [27] has demonstrated that en-
dogenous ABCC11 mRNA levels in breast cell lines are directly 
correlated with the estrogen receptor -status. Interestingly, they 
found that ABCC11 expression was reduced in vitro by estradiol 
treatments. Furthermore, this estradiol-dependent down-regulation 
of ABCC11 expression was blocked by co-treatment of tamoxifen 
(Fig. (3)), an antagonist of estradiol. These findings suggest 
ABCC11 expression is directly or indirectly regulated by estrogen 
receptor  and that the prolonged exposure of breast cancer cells to 
tamoxifen can lead to up-regulation of ABCC11. 
 Hauswald  et al. [28], on the other hand, have shown that some 
of histone deacetylase inhibitors induced the expression of several 
ABC transporters, including ABCC11 gene, to render acute myeloid 
leukemia cells a broad-spectrum of drug resistance. Molecular 
mechanisms underlying the induction remain to be elucidated. 
Since histone deacetylase inhibitors can be utilized in combination 
with conventional anti-cancer drugs in clinical trials, such induction 
of ABCC11 WT may affect the efficacy of nucleoside-based che-
motherapy. 
4. ER-ASSOCIATED DEGRADATION OF ABCC11 
  ABCC11 WT is an N-linked glycosylated protein, which is 
localized in intracellular granules and large vacuoles as well as at 
the luminal membrane of secretory cells in the cerumen apocrine 
gland [14]. N-linked glycosylation occurs at both Asn838 and 
Asn844 in the extracellular loop between transmembrane domains 7 
(TM7) and 8 (TM8) of the ABCC11 WT protein. In contrast, the 
SNP variant: ABCC11 Arg180, which is the determinant of human 
earwax type (as we see later in this review), lacks N-linked glycosy-
lation and readily undergoes proteasomal degradation, most proba-
bly via ubiquitination. 
  The ER and Golgi apparatus are the sites of synthesis and matu-
ration of proteins destined for the plasma membrane, for the secre-
tory and endocytic organelles, and for secretion [29, 30]. Efficient 
quality control systems have evolved to prevent incompletely 
folded proteins from moving along the secretory pathway. Accumu-
lation of misfolded proteins in the ER would detrimentally affect 
cellular functions. Therefore, misfolded proteins may be removed 
from the ER by retrotranslocation to the cytosol compartment 
where they are degraded by the ubiquitin-proteasome system. This 
process is known as endoplasmic reticulum-associated degradation 
(ERAD) [31-34]. It is likely that the SNP variant (Arg180) is rec-
ognized as misfolded proteins in the ER and readily undergoes 
proteasomal degradation. We consider that an electrostatic charge 
(either positive or negative) at amino acid 180 in transmembrane 
domain 1 (TM1) interferes with correct folding of de novo synthe-
sized ABCC11 protein in the ER [14]. This ERAD processing of 
the SNP variant (Arg180) of ABCC11 may greatly influence the 
activity of ceruminous apocrine glands and determine the type of 
human earwax. Similar ERAD processing is considered to take 
place for the SNP variant (Arg180) of ABCC11 in axillary and 
mammary apocrine glands. In Fig. (4), we schematically illustrate 
the impact of the SNP on the cellular localization and function of 
ABCC11 in secretory cells of the apocrine gland. Asn838 and 
Asn844 are glycosylation target sites in human ABCC11. The N-Pharmacogenomics of Human ABCC11  Anti-Cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 8    619 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). (A). Chemical structures of classical substrates of ABCC11. cAMP (cyclic adenosine monophosphate), cGMP (cyclic guanosine monophosphate), 
LTC4 (leukotriene C4), DNP-SG (S-(2,4-dinitrophenyl)-glutathione), E13S (estrone 3-sulfate), DHEAS (dehydroepiandrosterone 3-sulfate), and E217G (estra-
diol 17--D-glucuronide). (B) Anticancer drugs that are transported by ABCC11. MTA (pemetrexed), MTX, (methotrexate), Ara-C (Cytosine arabinoside), 
PMEA (9’-(2’-phosphonyl-methoxyethyl)adenine) are substrate for ABCC11. 5-fluoro-2’-deoxyuridine 5’-monophosphate (FdUMP) is an active metabolite of 
5-FU (5-fluorouracil) and transported by ABCC11. 
Table 1.  Kinetic Parameters for ABCC11-Mediated Transport 
Substrates Km  [μM] Vmax  [pmol/mg/min] Reference 
cGMP 7.8  -  Yoshiura  et al. 2005 [35] 
DHEAS 13.0  34.9  Chen  et al. 2005 [24] 
 21.0  370.0  Bortfeld  et al. 2006 [23] 
E217G 62.9  62.0  Chen  et al. 2005 [24] 
E1S3 150.0  -  Bortfeld  et al. 2006 [23] 
MTX 957.0 317.0  Chen  et al. 2005 [24] 620    Anti-Cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 8  Toyoda and Ishikawa 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Anticancer drugs that regulate the expression of ABCC11. SAHA 
(suberoylanilide hydroxamic acid), one of the histone deacetylase inhibitors, 
induces the expression of ABCC11 mRNA. Estradiol reduces the expression 
of ABCC11 transcript in estrogen receptor--positive breast cancer cells, 
whereas TAM (tamoxifen), an estrogen receptor- antagonist, abrogates the 
estrogen-mediated down-regulation effect. 
 
linked glycans are thought to be subjected to extensive modification 
as glycoproteins mature and move through the ER via the Golgi 
apparatus to their final destination, for example intracellular gran-
ules and large vacuoles of secretory cells in the apocrine gland. 
5. POLYMORPHISMS/GENETICS 
  Hitherto more than 10 non-synonymous single nucleotide po-
lymorphisms (SNPs) have been reported in the human ABCC11 
gene (Fig. (1B)). Among those SNPs, we have recently found that 
one SNP (rs17822931; 538G>A, Gly180Arg) determines the hu-
man earwax type [35]. Earwax (cerumen) is a secretory product of 
the ceruminous apocrine glands, which can be classified into two 
phenotypes in humans, wet (sticky) and dry. The dry type is mostly 
common in the Asian population, especially in Korean, Japanese, 
and Chinese, whereas the wet type is a dominant phenotype for 
many Africans and Caucasians. The AA genotype gives the dry 
phenotype, whereas both GA and GG genotypes give the wet phe-
notype. This is consistent with observations that earwax type is a 
Mendelian trait and that the wet phenotype is dominant to the dry 
one.  
  Interestingly, this SNP exhibits wide ethnic differences in the 
allele frequency [14]. In Mongoloid populations in Asia, the fre-
quency of the A allele is predominantly high, whereas its allele 
frequency is low among Caucasians and Africans [14, 35] (Fig. 
(5)). The frequency of the A allele exhibits a north-south and east-
west downward geographical gradient with the highest peak in 
northeastern Asia. It is suggested that the A allele arose in northeast 
Asia and thereafter spread throughout the world [35], apparently 
reflecting the inter-continental migration of Homo sapiens [14]. A 
similar west-east downward geographical gradient was observed in 
the frequency of the 2677G (Ala893) allele of the ABCB1 ( P-
glycoprotein/MDR1) gene as well [36]. 
6. PHYSIOLOGICAL FUNCTION OF ABCC11 
  Why does one SNP (538G>A) in the human ABCC11 gene 
affect the function of apocrine glands? For this question, we have 
recently provided evidence that proteasomal degradation of the 
SNP variant (Arg180) of ABCC11 is the underlying molecular 
mechanism [14]. Immunohistochemical studies with cerumen 
gland-containing tissue specimens revealed that the ABCC11 WT 
protein with Gly180 was expressed in the cerumen gland [14]. In-
terestingly, ABCC11 was predominantly localized in intracellular 
granules and large vacuoles in the secretory cells of wet-type ceru-
minous glands. In contrast, such granular and vacuolar localization 
of ABCC11 was not detected in the dry-type ceruminous glands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Schematic illustration of intracellular sorting of ABCC11 WT and proteasomal degradation of the R180 (Arg180) variant in secretory cells of the 
ceruminous apocrine gland. De novo synthesized ABCC11 WT is N-linked glycosylated at Asn838 and Asn844 in the ER, further processed in the Golgi appa-
ratus, and destined for membrane of intracellular granules and vacuoles. Ceruminous components are thought to be transported by ABCC11 WT and seques-
trated in intracellular granules and vacuoles. SNP variant R180 lacking N-linked glycosylation is recognized as misfolded proteins in the ER and readily un-
dergo ubiquitination and proteasomal degradation (ERAD pathway). ER, endoplasmic reticulum; ERAD, ER-associated degradation. Pharmacogenomics of Human ABCC11  Anti-Cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 8    621 
  Furthermore, morphological differences were previously re-
ported between the secretory cells of wet and dry types of human 
ceruminous glands [37]. In the wet-type glands, the Golgi apparatus 
was reportedly well developed, whereas it was generally small in 
the corresponding cells of the dry type. In addition, intracellular 
granules were abundantly observed in the wet-type gland in close 
relationship to their well-developed Golgi apparatus, whereas intra-
cellular granules were rare in the dry-type gland. 
  The cerumen gland is one of the apocrine glands. Apocrine 
glands can be found not only in the external auditory canal but also 
in the axillary region and breast; those physical characteristics also 
are concerned with apocrine glands. In fact, there is a positive asso-
ciation among the wet earwax type, axillary osmidrosis [38], and 
colostrum secretion from the breast [39]. Therefore, we suppose 
that ABCC11 WT would regulate the activity and/or development 
of apocrine glands in human. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). The allele frequencies of the wild type (WT, Gly180) and the 
538G>A (Arg180) variant of human ABCC11 among different ethnic popu-
lations. Data are from Yoshiura et al. [25]. 
7. APOCRINE PHENOTYPE 
  Apocrine secretion occurs when the secretory process is ac-
complished with a partial loss of cell cytoplasm. The secretory ma-
terials may be contained within the secretory vesicles or dissolved 
in the cytoplasm, and during secretion they are released as cyto-
plasmic fragments into the glandular lumen or interstitial space 
[40]. Hitherto apocrine secretory mechanisms have not been well 
characterized [40]. Although the biochemical and physiological 
pathways that regulate the apocrine secretory process are not clearly 
known, our recent findings [13, 14, 35] that the SNP (538G>A, 
Gly180Arg) in the ABCC11 gene determines the type of earwax 
and axillary osmidrosis have shed light on the novel function of this 
ABC transporter in apocrine glands. 
  In Japan, axillary osmidrosis is recognized as a disease that is 
covered by the national health insurance system. Axillary osmidro-
sis is often perceived, especially by young women, as a distressing 
and troublesome problem. Certain people display an excessive fear, 
aversion or psychological hypersensitivity to smells or odors. They 
tend to opt for aggressive surgical treatments and are sometimes 
categorized as having osmophobia.  
  Sweat produced by axillary apocrine glands is odorless. Secre-
tions from the apocrine glands, however, can be converted to odor-
iferous compounds by bacteria (Corynebacteria), which results in 
the formation of the unique “human axillary odor” [41]. In axillary 
osmidrosis patients (G/G homozygote or G/A heterozygote), sig-
nificantly numerous and larger-sized axillary apocrine glands were 
observed as compared with the subjects carrying the A/A homozy-
gote. Indeed, the 538G allele of the ABCC11 gene is associated 
with axillary osmidrosis [13-15] and ABCC11 WT (Gly180) is 
responsible for the secretion of pre-odoriferous compounds from 
the axillary apocrine gland. In primates, the axillary odors may play 
a role in olfactory communication, although no documented behav-
ioral or endocrine changes by volatiles produced in the axillae have 
been reported to occur in humans. Previous studies have shown that 
androgen steroids were present in the axillary area. Androsterone 
sulfate (AS) and dehydroepiandrostenedione sulphate (DHEAS) 
were detected in the extract of axillary hairs, in addition to high 
levels of cholesterol [42]. It was also demonstrated, following injec-
tion of radioactive pregnenolone or progesterone, that steroid secre-
tion was concentrated in the axillary area [43]. The axillary sweat 
collected in these studies from the skin surface, however, represents 
a mixture of materials from apocrine, eccrine, and sebaceous 
glands, in addition to desquamating epidermal cells. In this respect, 
Labows et al. [44] demonstrated that at least two androgen steroids, 
AS and DHEAS, in addition to cholesterol, did exist in pure apo-
crine secretions. It is strongly suggested that one of the physiologi-
cal functions of ABCC11 WT is active transport of steroid metabo-
lites, such as AS and DHEAS, into the lumen of apocrine glands. 
8. ABCC11 WILD TYPE ALLELE AND BREAST CANCER 
RISK 
  In 1971, Nicholas L. Petrakis first reported that international 
mortality and frequency rates for breast cancer seemed to be associ-
ated with the frequency of the allele for wet-type earwax [45]. Cau-
casians and African-Americans in the USA as well as Germans 
exhibited approximately four-fold higher rates of breast cancer 
mortality as compared with Japanese and Taiwanese women [45]. 
Nevertheless, the phenotypic association of the wet type of earwax 
with breast cancer has remained to be controversial [45, 46]. 
  At the present time, it is not well understood whether ABCC11 
WT really contributes to breast cancer risk. Therefore, we have 
most recently carried out the genotyping of the SNP 538G>A 
(Gly180Arg) with a total of 543 Japanese women to examine the 
association between the frequency rate of breast cancer and the 
allele frequency of the G allele (WT). Using blood samples from 
patients with invasive breast cancer (n = 270) and control volun-
teers (n = 273), we have genotyped the SNP 538G>A in the 
ABCC11 gene. The frequency of the G allele in the breast cancer 
patients was higher than that in the control volunteers. The odds 
ratio for the genotypes (G/G + G/A) in developing breast cancer 
was estimated as 1.63 (p-value = 0.026), suggesting that the G al-
lele in the ABCC11 gene is moderately associated with the risk of 
breast cancer [47]. Genetically-determined variations in the apo-
crine gland might influence susceptibility to breast cancer. We hy-
pothesize that the function of ABCC11 per se or metabolites trans-
ported by ABCC11 may stimulate the proliferation of apocrine 
gland cells to enhance the risk of mastopathy (Fig. (6)). This hy-
pothesis is supported by evidence that apocrine glands are large in 
individuals carrying WT allele of ABCC11 gene. As far as the cell 
cycle machinery is operating normally, proliferation of apocrine 
gland cells should stop to certain extent. However, when somatic 
mutation has occurred in BRCA1, BRCA2, p53, or p21 genes, it can 
start deleterious and unregulated proliferation of those cells Fig. (6). 
9. RELEVANCE TO DRUG RESISTANCE IN CANCER 
CHEMOTHERAPY 
  It has recently been reported that ABCC11 is potentially in-
volved in drug resistance of breast cancer. ABCC11 mRNA is 
highly expressed in breast tumors [19, 21, 25], in particular, in in-
vasive ductal adenocarcinomas (https://www.oncomine.org/ re-
source/logn.html). Its expression is reportedly regulated by estrogen 622    Anti-Cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 8  Toyoda and Ishikawa 
receptor- [27] and induced by 5-fluorouracil (5-FU) [48]. In addi-
tion, it has been reported that ABCC11 is directly involved in 5-FU 
resistance by the efflux transport of the active metabolite 5-fluoro-
2’-deoxyuridine 5’-monophosphate (FdUMP) [48-50]. It is of great 
interest to investigate whether the expression of ABCC11 WT 
(538G) is related to drug resistance of breast cancer and high rates 
of mortality. Further clinical studies, including protein expression 
studies in tumors, will be needed to clarify the potential contribu-
tion of ABCC11 to breast cancer risk and prognosis, including drug 
resistance and chemosensitivity. 
  Because of these structural similarities, it could be anticipated 
that substrate specificities of ABCC11 would be related to ABCC4 
and ABCC5. This indeed has been the case. Ectopic expression of 
ABCC11 in mammalian cells enhances the cellular
 efflux of cyclic 
nucleotides and confers resistance to certain
 anticancer and antiviral 
nucleotide analogues [50]. In fact, it has been reported that 
ABCC11 WT has an ability to efflux cyclic nucleotides (e.g., 
cGMP and cAMP) and confers resistance to several antiviral and 
anticancer nucleotide analogues, such as 5’-FdUMP and 9’-(2’-
phosohonylmethoxynyl)adenine (PMEA) [48-50]. 
  Therapy with nucleoside-derived drugs is characterized by in-
ter-individual variability [51, 52]. Genetic variants that affect pro-
tein products involved in all steps leading to drug action maybe 
major contributors to this heterogeneity of response to nucleoside-
based treatments. In particular, variants of drug metabolizing en-
zymes and transporters might determine the amount of drug needed 
for an efficient therapeutic response [6]. 
  Successful treatment of cancer remains a therapeutic challenge, 
with a high percentage of patients suffering from resistance or re-
lapsed disease. One of such examples resides in antileukemic 
treatment with nucleoside analogues, such as cytarabine (Ara-C) 
(Fig. (2B)). Guo et al. have recently presented evidence that expres-
sion of ABCC11 WT is an important factor in acute myeloid leu-
kemia patient survival and that the cause of treatment failure in 
those patients with high expression of ABCC11 WT is very likely 
an increased extrusion of Ara-C from blast cells mediated by the 
transporter [53]. 
 Uemura  et al. have recently found that the gene and protein 
expression of ABCC11 was higher in pemetrexed (MTA)-resistant 
cells than in the parental cells [54]. The MTA resistant cells showed 
cross-resistance to methotrexate (MTX) (Fig. (2B)), which is a 
substrate for ABCC11, and intracellular MTX accumulation in 
MTA-resistant cells was lower than in the parental cells. They then 
tested the effect of decreasing the expression of ABCC11 by siRNA 
and found that decreased expression of ABCC11 enhanced MTA 
cytotoxicity and increased intracellular MTX accumulation in 
MTA-resistant cells. These findings suggest that ABCC11 confers 
resistance to MTA by enhancing efflux of the intracellular anti-
cancer drug. 
  They further analyzed the relationship between ABCC11 gene 
expression and MTA sensitivity of 13 adenocarcinoma cell lines. In 
contrast to their expectation, there was no correlation. Instead, 13 
lung adenocarcinoma cell lines could be classified into three groups 
based on the genotype of the ABCC11 SNP (538G>A): G/G, G/A, 
and A/A. The A/A group showed a significant reduction in the IC50 
value of MTA compared with the combined G/G and G/A groups, 
indicating that the SNP (538G>A) in the ABCC11 gene is an impor-
tant determinant of MTA sensitivity. These results suggest that the 
SNP (538G>A) of the ABCC11 gene may be one of the biomarkers 
for MTA treatment in adenocarcinomas. 
CONCLUSIONS 
  In this review article, we have addressed the potential impact of 
ABCC11 538G>A on the apocrine phenotype, patients’ response to 
nucleoside-based chemotherapy, and the potential risk of breast 
cancer. However, it should be carefully evaluated by clinical studies 
whether the SNP (538G>A) of the ABCC11 gene is a clinically 
important biomarker for prediction of chemotherapeutic efficacy. In 
addition, we need to further elucidate whether there are any other 
diseases that involve apocrine secretion and to explore the clinical 
significance of ABCC11. 
  Pharmacogenomic studies are rapidly elucidating the inherited 
nature of differences in pharmacokinetic and pharmacodynamic 
effects, thereby enhancing drug discovery and providing a stronger 
scientific basis for optimizing drug therapy on the basis of each 
patient’s genetic constitution. For the next step, therefore, develop-
ment of new technology (e.g., rapid, accurate, and cost-effective 
diagnosis methods) is needed to facilitate clinical research of 
pharamacogenomics and to support genotyping-based personalized 
medicine. 
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